Search | IOVS | ARVO Journals

Showing 1 – 17 of 17

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Pooled safety analysis of the CANDELA, PHOTON, and PULSAR trials up to 96 weeks demonstrates comparable safety profiles with aflibercept 8 mg and 2 mg

Andreas Stahl; Eric Schneider; Ursula Maria Schmidt-Ott; Claudia Tueckmantel; Andrea Schulze; Alyson J Berliner; Karen W Chu; Robert Vitti; Kimberly Reed; xin Zhang; Peter Morgan-Warren; Rohini Rao; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):217.

ARVO Annual Meeting Abstract June 2017

A novel structural variant in VIEW1 neovascular age-related macular degeneration (AMD) patients

Lorah T Perlee; Robert Vitti

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):894.

ARVO Annual Meeting Abstract June 2017

Impact of baseline retinal nonperfusion on best corrected visual acuity in eyes with central retinal vein occlusion: post hoc analyses of COPERNICUS and GALILEO

David M Brown; Yuichiro Ogura; Francesco Boscia; Frank G Holz; Jean-Francois Korobelnik; Jeffrey Heier; Kay D Rittenhouse; Friedrich Asmus; Christiane Ahlers; Florian Hiemeyer; Chengxing Lu; Robert Vitti; Namrata Saroj; Nicolas Feltgen

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1559.

ARVO Annual Meeting Abstract September 2016

Interim results from the SATURN Study: Sarilumab in Non-infectious Uveitis (SARIL-NIU)

Quan Dong Nguyen; Preethi A Sundaram; Kristine Erickson; Rafael Varona; Laetitia Vinet; Valerie Corp-dit-Genti; Robert Vitti; Marc D de Smet

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1894.

ARVO Annual Meeting Abstract September 2016

Systemic Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor (VEGF) Agents in Patients With Wet Age-Related Macular Degeneration

Peter K Kaiser; Laurent Kodjikian; Jean-Francois Korobelnik; Oliver Zeitz; Robert Vitti; Carola Metzig; Christiane Ahlers; Thomas dicioccio; Joachim Hoechel

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3366.

ARVO Annual Meeting Abstract September 2016

Variability in vitreous haze grading technique using a 9-step logarithmic scale in patients enrolled in the Sarilumab in Non-infectious Uveitis (SARIL-NIU), the Saturn Study

Marc D de Smet; Preethi A Sundaram; Kristine Erickson; Valerie Corp-dit-Genti; Laetitia Vinet; Robert Vitti; Ronald BUGGAGE; Quan Dong Nguyen

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12)

ARVO Annual Meeting Abstract June 2015

The SATURN Study (SARIL-NIU): Sarilumab for the Treatment of Posterior Segment Non-Infectious Uveitis (NIU)

Quan Dong Nguyen; Preethi A Sundaram; Kristine Erickson; Rafael varona; David Drouot; Valerie Corp-dit-Genti; Husain Kazmi; Robert Vitti; Marc D de Smet; SATURN Study Group

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3116.

ARVO Annual Meeting Abstract April 2014

Efficacy and Safety of Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Pathological Myopia: 48-week Results of MYRROR Study

Tien Y Wong; Tatsuro Ishibashi; Kyoko Ohno-Matsui; Yasushi Ikuno; Jean-Francois Korobelnik; Brigitte Stemper; Yoshimi Matsuda; Tummy Li; Robert Vitti; Oliver Zeitz; MYRROR

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):4960.

ARVO Annual Meeting Abstract June 2013

Eighteen-Month Results of the GALILEO Study Evaluating Intravitreal Aflibercept Injection (IAI) for Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Yuichiro Ogura; Jean-Francois Korobelnik; Johann Roider; Robert Vitti; Frank Holz; Florian Hiemeyer; Brigitte Stemper; Oliver Zeitz; Rupert Sandbrink; GALILEO study investigators

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4516.

ARVO Annual Meeting Abstract March 2012

Intravitreal Aflibercept Injection in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 COPERNICUS Study

David M. Brown; Julia A. Haller; David S. Boyer; Jeffrey S. Heier; W. L. Clark; Alyson J. Berliner; Robert Vitti; Oliver Zeitz; Rupert Sandbrink

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):936.

ARVO Annual Meeting Abstract March 2012

Microperimetry assessment of retinal sensitivity in patients with diabetic macular edema - results from the Phase 2 Da Vinci study

Victor H. Gonzalez; Diana V. Do; Husain Kazmi; Robert Vitti; Alyson J. Berliner; Georg Groetzbach; Rupert Sandbrink; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2863.

ARVO Annual Meeting Abstract March 2012

Subgroup Efficacy Analyses of the VIEW 1 and VIEW 2 Studies of Intravitreal Aflibercept Injection and Ranibizumab for Treatment of Neovascular AMD

Allen C. Ho; Desmond Thompson; Robert Vitti; Yuhwen Soo; Alyson J. Berliner; Georg Groetzbach; Majid Anderesi; Rupert Sandbrink; Victor Chong; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):3678.

ARVO Annual Meeting Abstract March 2012

Intravitrial Aflibercept Injection for Macular Edema in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 GALILEO Study

Frank G. Holz; Yuichiro Ogura; Johann Roider; Jean-Francois Korobelnik; Brigitte Stemper; Robert Vitti; Alyson J. Berliner; Florian Hiemeyer; Rupert Sandbrink; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):6929.

ARVO Annual Meeting Abstract March 2012

Intraocular Pressure in Patients with Neovascular AMD Receiving Intravitreal Aflibercept Injection or Ranibizumab

K Bailey Freund; Robert Vitti; Yuhwen Soo; Desmond Thompson; Namrata Saroj; Alyson J. Berliner; Majid Anderesi; Olaf Sowade; Rupert Sandbrink

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2036.

ARVO Annual Meeting Abstract March 2012

Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW 2 Studies of Patients with Neovascular Age-related Macular Degeneration

Daniel B. Roth; Jeffrey S. Heier; Desmond Thompson; Yuhwen Soo; Robert Vitti; Namrata Saroj; Alyson J. Berliner; Georg Groeztbach; Olaf Sowade; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2042.

ARVO Annual Meeting Abstract April 2011

Randomized, Double-masked, Active-controlled Phase 3 Trial Of The Efficacy And Safety Of Intravitreal VEGF Trap-Eye In Wet AMD: One-year Results Of The View-1 Study

Quan D. Nguyen; Jeffery Heier; David Brown; Allen Ho; Peter Kaiser; Robert Vitti; VIEW 1 Study Group

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3073.

ARVO Annual Meeting Abstract April 2011

VEGF Trap-Eye In CRVO: Primary Endpoint Results Of The Phase 3 COPERNICUS Study

Julia A. Haller; David S. Boyer; Jeffrey S. Heier; David M. Brown; Lloyd Clark; Robert Vitti

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):6643.

NARROW

Content Type

Journal

Article Type

Specify Date Range

Pooled safety analysis of the CANDELA, PHOTON, and PULSAR trials up to 96 weeks demonstrates comparable safety profiles with aflibercept 8 mg and 2 mg

A novel structural variant in VIEW1 neovascular age-related macular degeneration (AMD) patients

Impact of baseline retinal nonperfusion on best corrected visual acuity in eyes with central retinal vein occlusion: post hoc analyses of COPERNICUS and GALILEO

Interim results from the SATURN Study: Sarilumab in Non-infectious Uveitis (SARIL-NIU)

Systemic Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor (VEGF) Agents in Patients With Wet Age-Related Macular Degeneration

Variability in vitreous haze grading technique using a 9-step logarithmic scale in patients enrolled in the Sarilumab in Non-infectious Uveitis (SARIL-NIU), the Saturn Study

The SATURN Study (SARIL-NIU): Sarilumab for the Treatment of Posterior Segment Non-Infectious Uveitis (NIU)

Efficacy and Safety of Intravitreal Aflibercept for Choroidal Neovascularization Secondary to Pathological Myopia: 48-week Results of MYRROR Study

Eighteen-Month Results of the GALILEO Study Evaluating Intravitreal Aflibercept Injection (IAI) for Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

Intravitreal Aflibercept Injection in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 COPERNICUS Study

Microperimetry assessment of retinal sensitivity in patients with diabetic macular edema - results from the Phase 2 Da Vinci study

Subgroup Efficacy Analyses of the VIEW 1 and VIEW 2 Studies of Intravitreal Aflibercept Injection and Ranibizumab for Treatment of Neovascular AMD

Intravitrial Aflibercept Injection for Macular Edema in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 GALILEO Study

Intraocular Pressure in Patients with Neovascular AMD Receiving Intravitreal Aflibercept Injection or Ranibizumab

Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW 2 Studies of Patients with Neovascular Age-related Macular Degeneration

Randomized, Double-masked, Active-controlled Phase 3 Trial Of The Efficacy And Safety Of Intravitreal VEGF Trap-Eye In Wet AMD: One-year Results Of The View-1 Study

VEGF Trap-Eye In CRVO: Primary Endpoint Results Of The Phase 3 COPERNICUS Study

To View More...

You must be signed into an individual account to use this feature.